Manufacturing Stopped At Seven Pharma Units

Solan : In a bid to ensure quality drug production, seven pharmaceutical firms were told to stop manufacturing in various pharmaceutical clusters after they were found not complying with the laid norms as enshrined in the Good Manufacturing Practices (GMP).

While the orders were revoked in six cases after a month of suspension by the drug authorities in January and February, one firm where the laxities were grave was yet to comply. The said firm has been directed to upgrade its facility to meet the norms.

As many as 35 firms were inspected during the first phase while another 35 were being inspected during the ongoing second phase, said officials. The action follows multiple cases of spurious drugs being manufactured in the state. Himachal houses around 650 drug firms, the maximum 450 being located in the Baddi-Barotiwala-Nalagarh industrial belt, called Asia’s pharmaceutical hub. The rest are in Paonta Sahib, Kala Amb and other parts. To identify potential hazards affecting the quality of drugs available to the common man, risk-based assessments are done in pharmaceutical firms from time to time.

State Drugs Controller Navneet Marwaha said the seven firms were issued “stop manufacturing” directions after shortcomings were found in the GMP compliance. He said while six of the companies subsequently complied with the laid norms, the seventh was upgrading its facility to meet the guidelines.

Marwaha said they conducted 3,000 inspections over the last three years with several firms being checked multiple times. He said 43 cases of non-compliance were found during the period.

Officials said critical observations such as “non-functional air handling units” and “dysfunctional lab equipment” in the micro-labs of these firms had come to the fore. As it could adversely affect the quality of drugs produced, all the firms were issued directions to stop manufacturing till their systems were rectified, the officials said.

  • Related Posts

    National Pharmaceutical Pricing Authority notifies retail price of 42 new drugs

    New Delhi:  The National Pharmaceutical Pricing Authority (NPPA) has notified retail price of 42 new drugs under the provisions of the Drugs Prices Control Order (DPCO), 2013, including anti hypertensive,…

    World’s First Malaria Treatment for Newborns and Young Infants Receives WHO Prequalification

    New Delhi– In a landmark development for global child health, the World Health Organization (WHO) has granted prequalification to Coartem® Baby (artemether-lumefantrine), the first and only antimalarial medicine specifically developed…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    National Pharmaceutical Pricing Authority notifies retail price of 42 new drugs

    National Pharmaceutical Pricing Authority notifies retail price of 42 new drugs

    World’s First Malaria Treatment for Newborns and Young Infants Receives WHO Prequalification

    World’s First Malaria Treatment for Newborns and Young Infants Receives WHO Prequalification

    FIR Lodged Against Pharmacist in Chandauli for Working Nearly 10 Years on Forged Documents

    FIR Lodged Against Pharmacist in Chandauli for Working Nearly 10 Years on Forged Documents

    Laughing all the Way to Health with Sir Ganga Ram Hospital

    Laughing all the Way to Health with Sir Ganga Ram Hospital

    Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

    Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

    Pak-made illegal cosmetics recovered from Itwari shop

    Pak-made illegal cosmetics recovered from Itwari shop